Study S000747

A Double-blind, Crossover, Randomized, Placebo-controlled Study to Investigate the Effect of Two Different Doses of Taspoglutide IRF Administered as Continuous Subcutaneous Infusion on First- and Second-phase Insulin Secretion in Type 2 Diabetic Patients

ClinicalTrials.gov record

Registration

Registration: NCT00811460
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 18
Start: 2008-11
Primary completion: 2009-08
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Placebo; DRUG:taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2008-003582-97; NIH:2008

Registered primary outcomes

Incremental area under insulin concentration time curve relative to basal insulin concentration [First 10 minutes after glucose bolus]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.